Skip to main content

Day: June 27, 2024

NORBIT to acquire the maritime technology company Innomar

Trondheim, 27 June 2024: NORBIT ASA (“NORBIT” or the “Company“) announces that it has entered into a share purchase agreement to acquire 100 per cent of the equity interest in the technology company INNOMAR Technologie GmbH (“Innomar“), the market leader in the field of sub-bottom profilers in the maritime industry. The acquisition of Innomar represents an attractive strategic fit with NORBIT as it contributes to broadening the product portfolio in the Oceans segment and diversifying its customer base. About InnomarHeadquartered in Rostock, Germany, Innomar is the global market leader in the design, manufacturing, and distribution of parametric sub-bottom profilers. With nearly thirty years of experience in acoustic systems, signal processing, maritime electronics, and software, Innomar has developed...

Continue reading

Acuity Brands Reports Fiscal 2024 Third-Quarter Results

Solid Execution Delivers Operating Margin Expansion, EPS Growth and Strong Operating Cash FlowDelivered Net Sales of $968M, a 3% Decline Compared to the Prior Year Grew Operating Profit to $145M, up 1% Over the Prior Year; Adjusted Operating Profit of $167M, up 3% Over the Prior Year Reported Diluted EPS of $3.62, up 10% Over the Prior Year; Adjusted Diluted EPS of $4.15, up 11% Over the Prior Year Generated $445M in Year-to-Date Cash Flow from OperationsATLANTA, June 27, 2024 (GLOBE NEWSWIRE) — Acuity Brands, Inc. (NYSE: AYI) (the “Company”), a market-leading industrial technology company, announced net sales of $968.1 million in the third quarter of fiscal 2024 ended May 31, 2024, a decrease of $32.2 million, or 3.2 percent, compared to the prior year. “In our fiscal 2024 third quarter we delivered solid results as we continued...

Continue reading

Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness

Planegg/Martinsried, June 27, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today provides a detailed overview of its lead candidate MDG1015, a first-in-class 3rd generation T cell receptor engineered T cell (TCR-T) therapy, at the 7th Cell and Gene Therapy In-Depth Focus Summit from June 27-28, 2024, in Beijing, China. MDG1015 advances towards the clinic and targets the cancer-testisantigens (CTA) NY-ESO-1 / LAGE-1a (New York esophageal squamous cell carcinoma 1 / L Antigen Family Member-1a) and is armored and enhanced by the Company’s PD1-41BB costimulatory switch protein (CSP). The presentation with the title “MDG1015: a 3rd Generation TCR-T Therapy Incorporating the PD1-41BB Costimulatory...

Continue reading

Form 8.3 – [MATTIOLI WOODS PLC] – 26 06 2024 – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree MATTIOLI WOODS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: MATTIOLI WOODS PLC AS AN ASSOCIATE...

Continue reading

Form 8.3 – [LOK’N STORE GROUP PLC] – 26 06 2024 – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LOK’N STORE GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Form 8.3 – [ KEYWORDS STUDIOS PLC] – 26 06 2024 – CGWL

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree KEYWORDS STUDIOS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Cost of new drug development is key concern for life science as focus shifts to repurposing

LONDON, June 27, 2024 (GLOBE NEWSWIRE) — 63% of life science companies believe the high cost of new drug development is among the emerging themes that will have the greatest negative impact on the sector in the next 3-5 years, according to Global life science risk report 2024 published today by WTW (NASDAQ: WTW), a leading global advisory, broking, and solutions company. This is leading to an increased focus on finding novel use cases for existing drugs, named by 66% as having a positive impact, as firms seek to launch new products and expand their international footprint. The 2nd life science global survey asked 400 senior decision makers belonging to pharmaceutical, biotech and other life science sector companies how they manage emerging risks and how they are preparing for the future. The survey also revealed that regulation...

Continue reading

Freshworks Unveils New Data Center in UAE to Serve Customers Across Middle East and Africa

DUBAI, UAE, June 27, 2024 (GLOBE NEWSWIRE) — Freshworks Inc. (NASDAQ: FRSH) today announced the launch of its new data center, powered by Amazon Web Services (AWS), in the UAE. This underscores Freshworks’ commitment to driving innovation across the Middle East and Africa (MEA) by making it easier for businesses to harness the full power of its modern, AI-powered customer and employee service solutions. “We are thrilled to further strengthen our presence in MEA with the new data center in UAE,” said Abe Smith, Chief of Global Field Operations at Freshworks. “This investment demonstrates our dedication to supporting the growth and digital transformation of businesses in the region. With our data center, companies requiring regional data compliance within the UAE can depend on us for business software in Customer Service, IT, and...

Continue reading

Scandinavian Tobacco Group A/S to acquire Mac Baren Tobacco Company A/S

Company Announcement No. 35/2024  Copenhagen, 27 June 2024 Scandinavian Tobacco Group A/S to acquire Mac Baren Tobacco Company A/S Scandinavian Tobacco Group has today agreed on the terms and conditions for the acquisition of all the shares of Mac Baren Tobacco Company A/S (“Mac Baren”) from Halberg A/S. On a debt and cash free basis (the enterprise value), the transaction is valued at DKK 535 million. The acquisition will be financed by cash at hand and debt. Closing of the transaction is expected shortly. Mac Baren is a family-owned business founded in 1826 and is a leading global smoking tobacco company, which includes a strong portfolio of pipe tobacco brands such as Mac Baren, Amphora and Holger Danske as well as fine-cut tobacco brands like Amsterdamer, Choice and Opal. The company also produces and sells nicotine pouches with...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.